Cogent Biosciences Inc (COGT)

$37.40 -0.47 (-1.24%)
Market Cap 6.57B
Revenue (ttm) 0.00
Net Income (ttm) -328.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.42
Volume 1,151,000
Avg Vol 2,505,480
Day's Range N/A - N/A
Shares Out 173.53M
Stochastic %K 13%
Beta 0.38
Analysts Strong Sell
Price Target $54.83

Company Profile

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stroma...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 945 5576
Address:
275 Wyman Street, 3rd Floor, Waltham, United States
Quantumup
Quantumup Aug. 12 at 11:36 AM
Guggenheim⬆️ $COGT's PT to $52 and keeps at a Buy rating. $PFE GSK BMPC - $SNY NVS CLDX OPHLY Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2087503305635229760?s=20
0 · Reply
Atomickb
Atomickb Aug. 11 at 2:21 PM
$COGT - hmm all that volume was for nothing. ? No buyout ?
0 · Reply
aristocks
aristocks Aug. 10 at 1:15 PM
$COGT earnings are out I think..
1 · Reply
Atomickb
Atomickb Aug. 9 at 2:05 AM
$COGT - Last monday or Tuesday there was high volume and high call volume on August 50 and 49 strikes. Amy idea why.
0 · Reply
Cap_00
Cap_00 Aug. 7 at 2:19 PM
$COGT Earnings not announced... fueling speculation of Buyout. If the do announce earnings, this is likely going down 5-10%... play safe.
1 · Reply
bio_stock
bio_stock Aug. 6 at 4:33 PM
$COGT when’s the earnings?
0 · Reply
BioRich
BioRich Aug. 4 at 8:16 PM
$XBI Today's Bio Winners: 1) $EWTX 2) $COGT 3) $DRTS 4) $ANVS 5) VVOS (Going wild AH). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
Doozio
Doozio Aug. 4 at 7:38 PM
$COGT …….
0 · Reply
QuantInsider
QuantInsider Aug. 4 at 5:57 PM
$COGT is on fire with a sharp momentum breakout We're seeing concentrated buying of those Aug 21 $50 calls 1,272 swept at the ask for around $88K Volume is beating open interest with no put flow in sight This is a big short term upside bet Stock is up about 10.5% today and 7.7% over five days There's no confirmed news driving it This is pure momentum so keep an eye on $50 It could reverse quickly if the speculative demand fades Tight risk control is key here
0 · Reply
CrispDry
CrispDry Aug. 4 at 5:39 PM
$COGT $58-60 buyout target - let’s get it done
0 · Reply
Latest News on COGT
Cogent Biosciences price target raised to $55 from $52 at Piper Sandler

2026-08-17T11:05:53.000Z - 2 days ago

Cogent Biosciences price target raised to $55 from $52 at Piper Sandler

Cogent Biosciences price target raised to $52 from $45 at Guggenheim

2026-08-17T10:02:15.000Z - 2 days ago

Cogent Biosciences price target raised to $52 from $45 at Guggenheim

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Cogent Biosciences Earnings release: Q2 2026

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Cogent Biosciences Earnings release: Q2 2026

Cogent Biosciences Quarterly report: Q2 2026

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Cogent Biosciences Quarterly report: Q2 2026

Cogent Biosciences submits bezuclastinib NDA to FDA

2026-06-30T12:16:19.000Z - 7 weeks ago

Cogent Biosciences submits bezuclastinib NDA to FDA

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Jun 30, 2026, 8:00 AM EDT - 7 weeks ago

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Jun 12, 2026, 8:01 AM EDT - 2 months ago

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Jun 12, 2026, 8:00 AM EDT - 2 months ago

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 2 months ago

Cogent Biosciences Transcript: AGM 2026

Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:05 AM EDT - 2 months ago

Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Cogent Biosciences announces data from analysis of PEAK Phase 3 trial

2026-05-31T20:35:51.000Z - 2 months ago

Cogent Biosciences announces data from analysis of PEAK Phase 3 trial

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2026, 8:00 AM EDT - 2 months ago

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Cogent Biosciences announces FDA acceptance of bezuclastinib NDA

2026-05-28T12:52:52.000Z - 2 months ago

Cogent Biosciences announces FDA acceptance of bezuclastinib NDA

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

May 28, 2026, 8:00 AM EDT - 2 months ago

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

May 27, 2026, 8:00 AM EDT - 3 months ago

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

May 12, 2026, 9:30 AM EDT - 3 months ago

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright

2026-05-07T09:54:00.000Z - 3 months ago

Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 5, 2026, 8:00 AM EDT - 3 months ago

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

Cogent Biosciences Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Cogent Biosciences Earnings release: Q1 2026

Cogent Biosciences Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Cogent Biosciences Quarterly report: Q1 2026

Cogent Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Cogent Biosciences Proxy statement: Proxy filing

Cogent Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Cogent Biosciences Proxy statement: Proxy filing

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs

2026-04-17T12:23:01.000Z - 4 months ago

Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Cogent Biosciences submits bezuclastinib new drug application to the FDA

2026-04-01T12:15:59.000Z - 5 months ago

Cogent Biosciences submits bezuclastinib new drug application to the FDA

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Apr 1, 2026, 8:00 AM EDT - 5 months ago

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Cogent Biosciences Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Cogent Biosciences Slides: Corporate presentation

Cogent Biosciences assumed with a Buy at Jefferies

2026-03-16T13:26:11.000Z - 5 months ago

Cogent Biosciences assumed with a Buy at Jefferies

Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM

2026-03-16T12:12:56.000Z - 5 months ago

Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:40 AM EDT - 5 months ago

Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2026

Cogent announces additional results from SUMMIT trial of bezuclastinib

2026-03-01T16:15:06.000Z - 6 months ago

Cogent announces additional results from SUMMIT trial of bezuclastinib

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Feb 28, 2026, 9:45 AM EST - 6 months ago

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

Cogent Biosciences price target raised to $35 from $34 at Baird

2026-02-19T14:00:31.000Z - 6 months ago

Cogent Biosciences price target raised to $35 from $34 at Baird

Cogent Biosciences price target raised to $52 from $39 at Piper Sandler

2026-02-18T11:45:45.000Z - 6 months ago

Cogent Biosciences price target raised to $52 from $39 at Piper Sandler

Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year

2026-02-17T13:06:13.000Z - 6 months ago

Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year

Cogent Biosciences sees cash runway into 2028

2026-02-17T13:05:46.000Z - 6 months ago

Cogent Biosciences sees cash runway into 2028

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Feb 17, 2026, 8:00 AM EST - 6 months ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Cogent Biosciences Annual report: Q4 2025

Feb 17, 2026, 8:00 AM EST - 6 months ago

Cogent Biosciences Annual report: Q4 2025

Cogent Biosciences Earnings release: Q4 2025

Feb 17, 2026, 8:00 AM EST - 6 months ago

Cogent Biosciences Earnings release: Q4 2025

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

Feb 10, 2026, 8:00 AM EST - 6 months ago

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

Cogent Biosciences announcse U.S. BTD for bezuclastinib

2026-01-26T13:06:30.000Z - 7 months ago

Cogent Biosciences announcse U.S. BTD for bezuclastinib

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

Jan 26, 2026, 8:00 AM EST - 7 months ago

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC FBYD FRGE INBX KOD LITE

Cogent to initiate New Drug Application submission for bezuclastinib

2026-01-20T13:05:25.000Z - 7 months ago

Cogent to initiate New Drug Application submission for bezuclastinib

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

Jan 20, 2026, 8:00 AM EST - 7 months ago

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

Cogent Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 7 months ago

Cogent Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Cogent Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 7 months ago

Cogent Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Cogent Biosciences announces anticipated 2026 commercial, clinical milestones

2026-01-12T13:20:52.000Z - 7 months ago

Cogent Biosciences announces anticipated 2026 commercial, clinical milestones

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

Jan 12, 2026, 8:00 AM EST - 7 months ago

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 8 months ago

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright

2026-01-06T11:10:22.000Z - 8 months ago

Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright

Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day.

Jan 2, 2026, 11:44 AM EST - 8 months ago

Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day.

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

Dec 30, 2025, 8:00 AM EST - 8 months ago

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

Cogent Biosciences Transcript: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Cogent Biosciences Transcript: Study Result

Cogent Biosciences Press release: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Cogent Biosciences Press release: Study Result

Cogent Biosciences Slides: Study Result

Dec 8, 2025, 8:00 AM EST - 9 months ago

Cogent Biosciences Slides: Study Result

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

Dec 6, 2025, 9:30 AM EST - 9 months ago

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

Cogent Biosciences Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 9 months ago

Cogent Biosciences Transcript: Jefferies London Healthcare Conference 2025

Cogent Biosciences Slides: FY 2025

Nov 19, 2025, 6:30 AM EST - 9 months ago

Cogent Biosciences Slides: FY 2025

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Nov 14, 2025, 8:00 AM EST - 9 months ago

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

Nov 11, 2025, 11:16 PM EST - 10 months ago

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Nov 10, 2025, 4:01 PM EST - 10 months ago

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Cogent Biosciences Transcript: Study Result

Nov 10, 2025, 8:00 AM EST - 10 months ago

Cogent Biosciences Transcript: Study Result

Cogent Biosciences Press release: Study Result

Nov 10, 2025, 8:00 AM EST - 10 months ago

Cogent Biosciences Press release: Study Result

Cogent Biosciences Slides: Study Result

Nov 10, 2025, 8:00 AM EST - 10 months ago

Cogent Biosciences Slides: Study Result

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

Nov 10, 2025, 7:00 AM EST - 10 months ago

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 3, 2025, 9:01 AM EST - 10 months ago

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

Nov 3, 2025, 9:00 AM EST - 10 months ago

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

Cogent Biosciences Quarterly report: Q3 2025

Nov 3, 2025, 9:00 AM EST - 10 months ago

Cogent Biosciences Quarterly report: Q3 2025

Cogent Biosciences Earnings release: Q3 2025

Nov 3, 2025, 9:00 AM EST - 10 months ago

Cogent Biosciences Earnings release: Q3 2025

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 24, 2025, 12:30 PM EDT - 10 months ago

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

Oct 20, 2025, 8:32 AM EDT - 10 months ago

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 29, 2025, 4:05 PM EDT - 11 months ago

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cogent Biosciences Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 9:00 AM EDT - 1 year ago

Cogent Biosciences Transcript: Citi's Biopharma Back to School Conference

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Cogent Biosciences Earnings release: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Cogent Biosciences Earnings release: Q2 2025

Cogent Biosciences Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Cogent Biosciences Quarterly report: Q2 2025

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 10, 2025, 4:01 PM EDT - 1 year ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Jul 8, 2025, 9:36 PM EDT - 1 year ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Jul 8, 2025, 4:26 PM EDT - 1 year ago

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Cogent Biosciences Transcript: Study Result

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Transcript: Study Result

Cogent Biosciences Press release: Study Result

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Press release: Study Result

Cogent Biosciences Slides: Study Result

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Slides: Study Result

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Jul 7, 2025, 7:06 AM EDT - 1 year ago

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Cogent Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Cogent Biosciences Slides: FY 2025

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Cogent Biosciences Slides: FY 2025

Cogent Biosciences Reports First Quarter 2025 Financial Results

May 6, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Reports First Quarter 2025 Financial Results

Cogent Biosciences Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Quarterly report: Q1 2025

Cogent Biosciences Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Earnings release: Q1 2025

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Apr 25, 2025, 8:08 AM EDT - 1 year ago

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Cogent Biosciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Proxy statement: Proxy Filing

Cogent Biosciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Proxy statement: Proxy Filing

Cogent Biosciences Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Cogent Biosciences Proxy statement: Proxy Filing

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 1 year ago

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2025

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Mar 7, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Feb 27, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Cogent Biosciences Annual report: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Annual report: Q4 2024

Cogent Biosciences Earnings release: Q4 2024

Feb 25, 2025, 8:00 AM EST - 1 year ago

Cogent Biosciences Earnings release: Q4 2024

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Feb 10, 2025, 9:15 AM EST - 1 year ago

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Cogent Biosciences Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 9:30 AM EST - 1 year ago

Cogent Biosciences Transcript: Guggenheim SMID Cap Biotech Conference

Cogent Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 10:30 AM EST - 1 year ago

Cogent Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Cogent Biosciences Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Dec 9, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Cogent Biosciences Slides: FY 2024

Dec 9, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Slides: FY 2024

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Dec 9, 2024, 7:00 AM EST - 1 year ago

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Dec 8, 2024, 12:00 PM EST - 1 year ago

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 9:30 AM EST - 1 year ago

Cogent Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Cogent Biosciences Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 7:30 AM EST - 1 year ago

Cogent Biosciences Transcript: Jefferies London Healthcare Conference 2024

Cogent Biosciences Transcript: Guggenheim Inaugural Global Healthcare Conference

Nov 12, 2024, 10:30 AM EST - 1 year ago

Cogent Biosciences Transcript: Guggenheim Inaugural Global Healthcare Conference

Cogent Biosciences Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Cogent Biosciences Quarterly report: Q3 2024

Cogent Biosciences Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Cogent Biosciences Earnings release: Q3 2024

Cogent Biosciences Quarterly report: Q2 2024

Aug 6, 2024, 8:15 AM EDT - 2 years ago

Cogent Biosciences Quarterly report: Q2 2024

Cogent Biosciences Earnings release: Q2 2024

Aug 6, 2024, 8:15 AM EDT - 2 years ago

Cogent Biosciences Earnings release: Q2 2024

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Jun 14, 2024, 7:30 AM EDT - 2 years ago

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Quantumup
Quantumup Aug. 12 at 11:36 AM
Guggenheim⬆️ $COGT's PT to $52 and keeps at a Buy rating. $PFE GSK BMPC - $SNY NVS CLDX OPHLY Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2087503305635229760?s=20
0 · Reply
Atomickb
Atomickb Aug. 11 at 2:21 PM
$COGT - hmm all that volume was for nothing. ? No buyout ?
0 · Reply
aristocks
aristocks Aug. 10 at 1:15 PM
$COGT earnings are out I think..
1 · Reply
Atomickb
Atomickb Aug. 9 at 2:05 AM
$COGT - Last monday or Tuesday there was high volume and high call volume on August 50 and 49 strikes. Amy idea why.
0 · Reply
Cap_00
Cap_00 Aug. 7 at 2:19 PM
$COGT Earnings not announced... fueling speculation of Buyout. If the do announce earnings, this is likely going down 5-10%... play safe.
1 · Reply
bio_stock
bio_stock Aug. 6 at 4:33 PM
$COGT when’s the earnings?
0 · Reply
BioRich
BioRich Aug. 4 at 8:16 PM
$XBI Today's Bio Winners: 1) $EWTX 2) $COGT 3) $DRTS 4) $ANVS 5) VVOS (Going wild AH). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
Doozio
Doozio Aug. 4 at 7:38 PM
$COGT …….
0 · Reply
QuantInsider
QuantInsider Aug. 4 at 5:57 PM
$COGT is on fire with a sharp momentum breakout We're seeing concentrated buying of those Aug 21 $50 calls 1,272 swept at the ask for around $88K Volume is beating open interest with no put flow in sight This is a big short term upside bet Stock is up about 10.5% today and 7.7% over five days There's no confirmed news driving it This is pure momentum so keep an eye on $50 It could reverse quickly if the speculative demand fades Tight risk control is key here
0 · Reply
CrispDry
CrispDry Aug. 4 at 5:39 PM
$COGT $58-60 buyout target - let’s get it done
0 · Reply
Doozio
Doozio Jul. 22 at 2:03 AM
$COGT out of the tightness ENTA 🐒🍌🧠⏰♾️
0 · Reply
FREEAMERICA
FREEAMERICA Jul. 17 at 2:06 PM
$COGT BUYOUT IMMINENT
0 · Reply
BlueSignal
BlueSignal Jul. 11 at 9:17 PM
$COGT stands out as a biotech with a much larger revenue potential being priced into the story. With a $6.6B market cap, investors are watching whether its pipeline can support a multi-billion-dollar sales opportunity. If execution matches expectations, the valuation discussion could shift significantly.
0 · Reply
FREEAMERICA
FREEAMERICA Jul. 9 at 12:54 PM
$COGT THIS ONE IS ABOUT TO BUST A MOVE
0 · Reply
bio_stock
bio_stock Jul. 8 at 8:40 PM
$COGT really good volume lately…
0 · Reply
ollifoo
ollifoo Jul. 6 at 6:47 PM
$COGT +30 +100 over 365 🪿
0 · Reply
RonIsWrong
RonIsWrong Jul. 6 at 4:38 PM
$COGT lots of folks posting the same chart, recognizing what could be an interesting move here. I'll add mine (rough)
1 · Reply
InvestorWisdom
InvestorWisdom Jul. 6 at 4:08 PM
$COGT showing strength above the trendline + 10ema is coming up under the price and could push it higher soon
0 · Reply
BioRich
BioRich Jul. 1 at 4:47 PM
$NNE Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) $IMVT 47) $MPLT 48) NNE 49) $ARDX 50) $COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
3 · Reply
Laynester
Laynester Jun. 30 at 4:18 PM
$RARE $NESR $IMMX $COGT $BCRX [DASH] [RKT] [BRBR] [INSM] [VKTX] [BBIO] [AG] [HL] [PSLV] Bears, Sell Calls, Buy Puts please document your BEAR CASE: MASSIVE PORTFOLIO BOTTOM UP SCANNER BUYS today: see attached image. All (any) national Patriot un predjudice Men secure your FAMILY, HOME, TOWN, STATE, BORDER and all FUTURE ELECTIONS. All for one! and One for all! Let's Roll! Set a stop. Good to all us "world slaves". All above and below 100% --->🦬
0 · Reply
Lanikai16
Lanikai16 Jun. 30 at 12:55 PM
$COGT Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-submission-new-drug-application-nda
0 · Reply
WAJeff
WAJeff Jun. 29 at 9:05 PM
$COGT Looks ready to go
0 · Reply